| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Anzalone Christopher Richard | Chief Executive Officer, Director | 177 E. COLORADO BLVD, SUITE 700, PASADENA | /s/Christopher Anzalone | 16 Dec 2025 | 0001423029 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ARWR | Common Stock | Award | $0 | +180K | +4.59% | $0.00 | 4.1M | 12 Dec 2025 | Direct | F1, F2 |
| transaction | ARWR | Common Stock | Sale | -$6.9M | -101K | -2.45% | $68.67 | 4M | 15 Dec 2025 | Direct | F2, F3, F4 |
| transaction | ARWR | Common Stock | Sale | -$1.48M | -21.3K | -0.53% | $69.28 | 3.98M | 15 Dec 2025 | Direct | F2, F3, F5 |
| transaction | ARWR | Common Stock | Sale | -$570K | -8.15K | -0.2% | $69.96 | 3.97M | 15 Dec 2025 | Direct | F2, F3, F6 |
| transaction | ARWR | Common Stock | Sale | -$509K | -8.42K | -0.21% | $60.51 | 3.96M | 16 Dec 2025 | Direct | F2, F3, F7 |
| transaction | ARWR | Common Stock | Sale | -$671K | -11K | -0.28% | $61.25 | 3.95M | 16 Dec 2025 | Direct | F2, F3, F8 |
| transaction | ARWR | Common Stock | Sale | -$876K | -14.1K | -0.36% | $62.12 | 3.94M | 16 Dec 2025 | Direct | F2, F3, F9 |
| transaction | ARWR | Common Stock | Sale | -$533K | -8.48K | -0.22% | $62.94 | 3.93M | 16 Dec 2025 | Direct | F2, F3, F10 |
| transaction | ARWR | Common Stock | Sale | -$428K | -6.66K | -0.17% | $64.29 | 3.92M | 16 Dec 2025 | Direct | F2, F3, F11 |
| transaction | ARWR | Common Stock | Sale | -$65K | -1K | -0.03% | $64.96 | 3.92M | 16 Dec 2025 | Direct | F2, F3, F12 |
| transaction | ARWR | Common Stock | Sale | -$85.5K | -1.3K | -0.03% | $65.77 | 3.92M | 16 Dec 2025 | Direct | F2, F3, F13 |
| transaction | ARWR | Common Stock | Sale | -$11.1K | -166 | 0% | $66.77 | 3.92M | 16 Dec 2025 | Direct | F2, F3, F14 |
| transaction | ARWR | Common Stock | Sale | -$219K | -3.22K | -0.08% | $67.87 | 3.92M | 16 Dec 2025 | Direct | F2, F3, F15 |
| Id | Content |
|---|---|
| F1 | Represents shares underlying restricted stock units with a grant date December 12, 2025, which will vest in four equal annual installments. |
| F2 | Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. |
| F3 | Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4. |
| F4 | The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.28 to $69.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| F5 | The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $69.01 to $69.75, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| F6 | The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $69.83 to $70.32, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| F7 | The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $59.73 to $60.70, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| F8 | The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $60.79 to $61.68, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| F9 | The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $61.72 to $62.60, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| F10 | The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $62.62 to $63.50, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| F11 | The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.56 to $64.45, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| F12 | The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $64.81 to $65.06, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| F13 | The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $65.63 to $65.96, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| F14 | The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.70 to $66.88, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| F15 | The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $67.70 to $68.05, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |